March 6, 2013

Grifols acquires 60% of the capital of Spanish biotechnology firm Progenika Biopharma

  ▪ Progenika specializes in the design and manufacture of in vitro genome-based diagnostic tests, prognosis of diseases and prediction of responses to pharmacological treatment. It is also a leader in the development of DNA-based prognosis and diagnostic technologies. ▪ The total value of the operation is 37 million euros. Payment has been a combination...
Read More